Search results
Results From The WOW.Com Content Network
Depressive disorder not otherwise specified (DD-NOS) is designated by the code 311 in the DSM-IV for depressive disorders that are impairing but do not fit any of the officially specified diagnoses. According to the DSM-IV, DD-NOS encompasses "any depressive disorder that does not meet the criteria for a specific disorder."
In medicine, not otherwise specified (NOS) is a subcategory in systems of disease/disorder classification such as ICD-9, ICD-10, or DSM-IV.It is generally used to note the presence of an illness where the symptoms presented were sufficient to make a general diagnosis, but where a specific diagnosis was not made.
The ones that were updated are marked yellow – the older ICD codes from ... Major depressive disorder, recurrent, unspecified: 296.2x: Major depressive disorder ...
296.xx Major depressive disorder.2x Major depressive disorder, single episode .26 In full remission.25 In partial remission.21 Mild.22 Moderate.23 Severe without psychotic features.24 Severe with psychotic features.20 Unspecified.3x Major depressive disorder, recurrent .36 In full remission.35 In partial remission.31 Mild.32 Moderate
The ICD-10 Clinical Modification (ICD-10-CM) is a set of diagnosis codes used in the United States of America. [1] It was developed by a component of the U.S. Department of Health and Human services, [ 2 ] as an adaption of the ICD-10 with authorization from the World Health Organization .
The DSM-5 (2013), the current version, also features ICD-9-CM codes, listing them alongside the codes of Chapter V of the ICD-10-CM. On 1 October 2015, the United States health care system officially switched from the ICD-9-CM to the ICD-10-CM. [1] [2] The DSM is the authoritative reference work in diagnosing mental disorders in the world.
From January 2008 to December 2012, if you bought shares in companies when Linda Fayne Levinson joined the board, and sold them when she left, you would have a -6.7 percent return on your investment, compared to a -2.8 percent return from the S&P 500.
Pioglitazone was patented in 1985, and came into medical use in 1999. [5] It is available as a generic medication. [3] In 2022, it was the 120th most commonly prescribed medication in the United States, with more than 5 million prescriptions. [6] [7] It was withdrawn in France and Germany in 2011. [8] [9] [10]